Previous Close | 72.96 |
Open | 72.88 |
Bid | 69.58 x 900 |
Ask | 73.00 x 900 |
Day's Range | 70.69 - 72.98 |
52 Week Range | 38.41 - 79.81 |
Volume | |
Avg. Volume | 596,654 |
Market Cap | 3.554B |
Beta (5Y Monthly) | 0.45 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.80 |
Earnings Date | Nov 02, 2022 - Nov 07, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 85.25 |
Subscribe to Yahoo Finance Plus to view Fair Value for AXNX
IRVINE, Calif., August 18, 2022--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that senior management is scheduled to present at the following investor conferences:
IRVINE, Calif., August 17, 2022--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that in the last twelve months, the United States Patent and Trademark Office has granted eight patents and allowed four patent applications related to the company’s sacral neuromodulation technology.
Does Axonics Modulation Technologies (AXNX) have what it takes to be a top stock pick for momentum investors? Let's find out.